People

Bio Cancer > People

People

Senior Management Team

Dr. Paul Cheng, MD

Co-Founder, Chief Executive Officer

Click for details

Derek Wong

Chief Financial Officer

Click for details

Dr. Ian Nelligan, PhD

Chief Technical Officer

Click for details

Board of Directors

Dr. Jun Sing Lee, PhD

Co-Founder,
Chairman of the Board

Click for details

Dr. Paul Cheng, MD

Co-Founder, Chief Executive Officer

Click for details

Dr. Lu Huang, MBA

 

Click for details

Derek Wong

Chief Financial Officer

Click for details

KC Poon

 

Click for details

Norman Tse

 

Click for details

Scientific Advisors

Professor Tony Mok

Professor, Department of Clinical Oncology,
the Chinese University of Hong Kong

Click for details

Dr. Francis Mussai

Clinical Senior Lecturer,
Department of Oncology, University of Birmingham

Click for details

Professor Gernot Schabbauer

Professor, Department of Physiology,
Medical University of Vienna

Click for details

Daniel Lee

Associate Vice-President and Chief Innovation and Enterprise Officer, Office of Innovation and Enterprise of the Chinese University of Hong Kong

Click for details
Copyright © 2001-2020 Bio-Cancer Treatment International Limited. All rights reserved.

Dr. Paul Cheng, MD

Co-Founder. Chief Executive Officer

Dr. Cheng who is a practicing medical oncologist and haematologist co-founded BCT with Dr. Jun Sing Lee in 2000. Dr. Cheng was on the faculty of medical school of University of Hong Kong from 1983 to 1984 and medical school of The Chinese University of Hong Kong from 1984 to 1989. He has extensive experience in research as well as clinical trials and is an author of over 30 publications in medical journals as well as a chapter of a textbook on oncology. His current research interests are arginine restriction in cancer therapy and cycle signaling control in cancer. Dr. Cheng graduated with MBBCh in 1979 from the University of Wales College of Medicine where he also obtained his haematology training and his MD. Dr. Cheng obtained his medical oncology training at Memorial Sloan-Kettering Cancer Center in the US.

Derek Wong

Chief Financial Officer

Mr. Wong joined BCT in early 2015. Prior to that, Mr. Wong has been managing his own family construction business for about 13 years. Previously, he was the financial controller of Chinadotcom, a Hong Kong based company listed on Nasdaq, for about two years. Mr. Wong was intimately involved in Chinadotcom’s IPO in 1999 and follow-on offering in 2000 before joining his family business. Previously, he was with Ernst & Young for about six years. Mr. Wong graduated from the University of Sydney in 1994 and is a member of the Institute of Chartered Accountants in Australia.

Dr. Ian Nelligan, PhD

Chief Technical Officer

Dr. Nelligan joined BCT in 2016 and has over 30 years of experience working with GSK and Wyeth (purchased by Pfizer in 2009) in Europe and the US in various technical and manufacturing positions. After leaving Wyeth Ireland in 2008 as Associate Director in Technical Operations Support, Ian joined the Irish Government to help lead the design, commissioning and start-up of a €57M industrial scale biopharmaceutical mAb production and fill finish training facility, National Institute for Bioprocessing Research and Training (NIBRT), as its Technical and Training Director to support the Irish Bioprocessing industry. Since leaving NIBRT in 2012, Dr. Nelligan has worked as an Auditor and Pharmaceutical Consultant advising and managing various projects including cleaning validation, fermentation optimization and contamination control. Dr. Nelligan has a PhD in control and optimization of microbial growth and penicillin production from Liverpool University.

Dr. Jun Sing Lee, PhD

Co-Founder, Chairman of the Board

Dr. Lee, who is a seasoned investor with successful experience in investing and building with a number of businesses ranging from realty to technology, is the co-founder of BCT with Dr. Paul Cheng in 2000. Dr. Lee has substantial experience serving on the boards of many companies, including Hong Kong-listed companies. Dr. Lee graduated from the College of Wooster in 1967 and completed his PhD study in Physical Chemistry at Indiana University at Bloomington in 1976. He did post-doctoral research at Johns Hopkins University through 1982 before his return to Hong Kong to pursue a business career.

Dr. Paul Cheng, MD

Co-Founder. Chief Executive Officer

Dr. Cheng is a practicing medical oncologist and haematologist who co-founded BCT with Dr. Jun Sing Lee in 2000. Dr. Cheng was on the faculty of medical school of The Chinese University of Hong Kong from 1984 to 1989. He has extensive experience in research as well as clinical trials and is an author of over 30 publications in medical journals as well as a chapter of a textbook on oncology. His current research interests are arginine restriction in cancer therapy and cycle signaling control in cancer. Dr. Cheng graduated with MBBCh in 1979 from the University of Wales College of Medicine where he also obtained his haematology training and his MD.Dr. Cheng obtained his medical oncology training at Memorial Sloan-Kettering Cancer Center in the US.

View Bio

Dr. Lu Huang, MBA

Dr. Huang, who joined our Board in 2017, is a Director of Morningside Asia Venture. Dr. Huang joined Morningside in 2003 and has been responsible for its healthcare and life science investments in Asia. Prior to joining Morningside, Dr. Huang served as a Marketing Associate at Continuum Health Partners, a five-hospital partnership in New York for a couple of years. Prior to that, Dr. Huang was a physician, specializing in obstetrics/gynecology. Dr. Huang graduated with a Bachelor degree in clinical medicine from Shanghai Jiao Tong University in 1997 and with a M.B.A. degree from St. John's University in the US in 2001.

Derek Wong

Chief Financial Officer

Mr. Wong joined BCT in early 2015. Prior to that, Mr. Wong has been managing his own family construction business for about 13 years. Previously, he was the financial controller of Chinadotcom, a Hong Kong based company listed on Nasdaq, for about two years. Mr. Wong was intimately involved in Chinadotcom’s IPO in 1999 and follow-on offering in 2000 before joining his family business. Previously, he was with Ernst & Young for about six years. Mr. Wong graduated from the University of Sydney in 1994 and is a member of the Institute of Chartered Accountants in Australia.

KC Poon

Mr Poon Kei Chak has over forty years of experience in the textile industry. He was formerly the executive vice chairman of Texwinca Holdings Limited (Stock Code: 321.hk). Mr Poon has been an active investor in the life sciences industry in recent years in support of the healthcare research and development in Hong Kong.

Norman Tse

Norman is currently an Assistant Vice President at Nan Fung Life Sciences focusing on early stage direct and fund investments in the life science sector. Before joining NFLS, he was responsible for managing a global healthcare equity portfolio at family office of Global Sources (NASDAQ: GSOL), which was sold to Blackstone for US$480M in 2017. Prior to that, he was with Uni-Bio Science Group (HKSE: 0690) and closed multiple licensing deals with leading China and Korea pharmaceutical companies. Norman earned a master degree in Bioengineering from UC Berkeley & UCSF and a bachelor degree in Biochemistry from the University of Hong Kong. He has completed the CFA program in 2017.

Professor Tony Mok

Professor, Department of Clinical Oncology, the Chinese University of Hong Kong

Professor Mok has been teaching at the Chinese University of Hong Kong medical school since 1996 after practising as an oncologist in Canada for eight years. Professor Mok is active in both clinical and laboratory research in lung cancer, liver cancer and traditional Chinese medicine. He is the founder of the Lung Cancer Research Group, one of the first multicentre lung cancer study groups in the Asia Pacific region. He chairs the Hong Kong Cancer Therapy Society and is an executive committee member of the Chinese Society of Clinical Oncology. In addition, he serves as a member of the Board of Directors for the International Association on Study of Lung Cancer. Professor Mok received his medical degree from the University of Alberta in Canada. His specialty is medical oncology.

Dr. Francis Mussai

Clinical Senior Lecturer, Department of Oncology, University of Birmingham

Dr. Mussai is a Clinical Senior Lecturer in Paediatric Oncology in the School of Cancer Sciences and an Honorary Consultant in Paediatric Oncology at the Birmingham Children’s Hospital. His research is focused on understanding the interaction between paediatric cancers and the immune system, in particular how cancers suppress the immune response to avoid destruction. In addition, Dr. Mussai aims to develop novel therapies for paediatric cancers, from pre-clinical studies through to early phase clinical trials. Dr. Mussai took his MA, MBBCh, and DPhil all from University of Oxford. He also had trainings at Johns Hopkins University and the National Cancer Institute in the US.

Professor Gernot Schabbauer

Professor, Department of Physiology, Medical University of Vienna

Professor Schabbauer has been doing research and teaching at the Medical University of Vienna since 2005. His main research interest has been the role of signaling pathways, such as the PI3K/PTEN axis, in myeloid cells modulating the inflammatory as well as the innate and adaptive immune response in different pathological settings. Professor Schabbauer took both his undergraduate studies in Genetics and Biochemistry and doctoral Studies in Genetics at the University of Vienna, Austria. He also had training as a Schrödinger Postdoctoral Fellow at the Institute of Immunology of The Scripps Research Institute in the US.

Daniel Lee

Daniel is a clinical biochemist by training and obtained his PhD in Pathology at the University of Hong Kong. He has serviced the pharmaceutical industry for over 25 years including JNJ, Biogen, GSK and lately served as General Manager and Head of site for Roche Pharma R&D China in Shanghai from 2010. He has broad experience in the drug discovery and development business, familiar in both small molecule and biologic drug discovery and development covering therapeutic areas from CNS, infectious diseases, diabetes complications to oncology and inflammation. Over the years he has published over 50 papers, actively engaged in teaching, grant/manuscript reviews, and named as a co-inventor for 15 patents. He served as Head of Biomedical Technology Cluster, Hong Kong Science and Technology Parks and engaged in repositioning the biomedical technology industry in Hong. He has been consulting for several institutes and biomedical technology companies, holds Adjunct Professorship of Division of Life Science, Hong Kong University of Science and Technology, Honorary Professorships of Faculty of Medicine, University of Hong Kong, and School of Biomedical Sciences, Chinese University of Hong Kong. He is currently Associate Vice-President and Chief Innovation and Enterprise Officer, Office of Innovation and Enterprise of the Chinese University of Hong Kong.

Dr. Paul Cheng, MD

Co-Founder. Chief Executive Officer

Dr. Cheng who is a practicing medical oncologist and haematologist co-founded BCT with Dr. Jun Sing Lee in 2000. Dr. Cheng was on the faculty of medical school of University of Hong Kong from 1983 to 1984 and medical school of The Chinese University of Hong Kong from 1984 to 1989. He has extensive experience in research as well as clinical trials and is an author of over 30 publications in medical journals as well as a chapter of a textbook on oncology. His current research interests are arginine restriction in cancer therapy and cycle signaling control in cancer. Dr. Cheng graduated with MBBCh in 1979 from the University of Wales College of Medicine where he also obtained his haematology training and his MD. Dr. Cheng obtained his medical oncology training at Memorial Sloan-Kettering Cancer Center in the US.

Derek Wong

Chief Financial Officer

Mr. Wong joined BCT in early 2015. Prior to that, Mr. Wong has been managing his own family construction business for about 13 years. Previously, he was the financial controller of Chinadotcom, a Hong Kong based company listed on Nasdaq, for about two years. Mr. Wong was intimately involved in Chinadotcom’s IPO in 1999 and follow-on offering in 2000 before joining his family business. Previously, he was with Ernst & Young for about six years. Mr. Wong graduated from the University of Sydney in 1994 and is a member of the Institute of Chartered Accountants in Australia.

Dr. Ian Nelligan, PhD

Chief Technical Officer

Dr. Nelligan joined BCT in 2016 and has over 30 years of experience working with GSK and Wyeth (purchased by Pfizer in 2009) in Europe and the US in various technical and manufacturing positions. After leaving Wyeth Ireland in 2008 as Associate Director in Technical Operations Support, Ian joined the Irish Government to help lead the design, commissioning and start-up of a €57M industrial scale biopharmaceutical mAb production and fill finish training facility, National Institute for Bioprocessing Research and Training (NIBRT), as its Technical and Training Director to support the Irish Bioprocessing industry. Since leaving NIBRT in 2012, Dr. Nelligan has worked as an Auditor and Pharmaceutical Consultant advising and managing various projects including cleaning validation, fermentation optimization and contamination control. Dr. Nelligan has a PhD in control and optimization of microbial growth and penicillin production from Liverpool University.

Dr. Jun Sing Lee, PhD

Co-Founder, Chairman of the Board

Dr. Lee, who is a seasoned investor with successful experience in investing and building with a number of businesses ranging from realty to technology, is the co-founder of BCT with Dr. Paul Cheng in 2000. Dr. Lee has substantial experience serving on the boards of many companies, including Hong Kong-listed companies. Dr. Lee graduated from the College of Wooster in 1967 and completed his PhD study in Physical Chemistry at Indiana University at Bloomington in 1976. He did post-doctoral research at Johns Hopkins University through 1982 before his return to Hong Kong to pursue a business career.

Dr. Paul Cheng, MD

Co-Founder. Chief Executive Officer

Dr. Cheng is a practicing medical oncologist and haematologist who co-founded BCT with Dr. Jun Sing Lee in 2000. Dr. Cheng was on the faculty of medical school of The Chinese University of Hong Kong from 1984 to 1989. He has extensive experience in research as well as clinical trials and is an author of over 30 publications in medical journals as well as a chapter of a textbook on oncology. His current research interests are arginine restriction in cancer therapy and cycle signaling control in cancer. Dr. Cheng graduated with MBBCh in 1979 from the University of Wales College of Medicine where he also obtained his haematology training and his MD.Dr. Cheng obtained his medical oncology training at Memorial Sloan-Kettering Cancer Center in the US.

View Bio

Dr. Lu Huang, MBA

Dr. Huang, who joined our Board in 2017, is a Director of Morningside Asia Venture. Dr. Huang joined Morningside in 2003 and has been responsible for its healthcare and life science investments in Asia. Prior to joining Morningside, Dr. Huang served as a Marketing Associate at Continuum Health Partners, a five-hospital partnership in New York for a couple of years. Prior to that, Dr. Huang was a physician, specializing in obstetrics/gynecology. Dr. Huang graduated with a Bachelor degree in clinical medicine from Shanghai Jiao Tong University in 1997 and with a M.B.A. degree from St. John's University in the US in 2001.

Derek Wong

Chief Financial Officer

Mr. Wong joined BCT in early 2015. Prior to that, Mr. Wong has been managing his own family construction business for about 13 years. Previously, he was the financial controller of Chinadotcom, a Hong Kong based company listed on Nasdaq, for about two years. Mr. Wong was intimately involved in Chinadotcom’s IPO in 1999 and follow-on offering in 2000 before joining his family business. Previously, he was with Ernst & Young for about six years. Mr. Wong graduated from the University of Sydney in 1994 and is a member of the Institute of Chartered Accountants in Australia.

KC Poon

Mr Poon Kei Chak has over forty years of experience in the textile industry. He was formerly the executive vice chairman of Texwinca Holdings Limited (Stock Code: 321.hk). Mr Poon has been an active investor in the life sciences industry in recent years in support of the healthcare research and development in Hong Kong.

Norman Tse

Norman is currently an Assistant Vice President at Nan Fung Life Sciences focusing on early stage direct and fund investments in the life science sector. Before joining NFLS, he was responsible for managing a global healthcare equity portfolio at family office of Global Sources (NASDAQ: GSOL), which was sold to Blackstone for US$480M in 2017. Prior to that, he was with Uni-Bio Science Group (HKSE: 0690) and closed multiple licensing deals with leading China and Korea pharmaceutical companies. Norman earned a master degree in Bioengineering from UC Berkeley & UCSF and a bachelor degree in Biochemistry from the University of Hong Kong. He has completed the CFA program in 2017.

Professor Tony Mok

Professor, Department of Clinical Oncology, the Chinese University of Hong Kong

Professor Mok has been teaching at the Chinese University of Hong Kong medical school since 1996 after practising as an oncologist in Canada for eight years. Professor Mok is active in both clinical and laboratory research in lung cancer, liver cancer and traditional Chinese medicine. He is the founder of the Lung Cancer Research Group, one of the first multicentre lung cancer study groups in the Asia Pacific region. He chairs the Hong Kong Cancer Therapy Society and is an executive committee member of the Chinese Society of Clinical Oncology. In addition, he serves as a member of the Board of Directors for the International Association on Study of Lung Cancer. Professor Mok received his medical degree from the University of Alberta in Canada. His specialty is medical oncology.

Dr. Francis Mussai

Clinical Senior Lecturer, Department of Oncology, University of Birmingham

Dr. Mussai is a Clinical Senior Lecturer in Paediatric Oncology in the School of Cancer Sciences and an Honorary Consultant in Paediatric Oncology at the Birmingham Children’s Hospital. His research is focused on understanding the interaction between paediatric cancers and the immune system, in particular how cancers suppress the immune response to avoid destruction. In addition, Dr. Mussai aims to develop novel therapies for paediatric cancers, from pre-clinical studies through to early phase clinical trials. Dr. Mussai took his MA, MBBCh, and DPhil all from University of Oxford. He also had trainings at Johns Hopkins University and the National Cancer Institute in the US.

Professor Gernot Schabbauer

Professor, Department of Physiology, Medical University of Vienna

Professor Schabbauer has been doing research and teaching at the Medical University of Vienna since 2005. His main research interest has been the role of signaling pathways, such as the PI3K/PTEN axis, in myeloid cells modulating the inflammatory as well as the innate and adaptive immune response in different pathological settings. Professor Schabbauer took both his undergraduate studies in Genetics and Biochemistry and doctoral Studies in Genetics at the University of Vienna, Austria. He also had training as a Schrödinger Postdoctoral Fellow at the Institute of Immunology of The Scripps Research Institute in the US.

Daniel Lee

Daniel is a clinical biochemist by training and obtained his PhD in Pathology at the University of Hong Kong. He has serviced the pharmaceutical industry for over 25 years including JNJ, Biogen, GSK and lately served as General Manager and Head of site for Roche Pharma R&D China in Shanghai from 2010. He has broad experience in the drug discovery and development business, familiar in both small molecule and biologic drug discovery and development covering therapeutic areas from CNS, infectious diseases, diabetes complications to oncology and inflammation. Over the years he has published over 50 papers, actively engaged in teaching, grant/manuscript reviews, and named as a co-inventor for 15 patents. He served as Head of Biomedical Technology Cluster, Hong Kong Science and Technology Parks and engaged in repositioning the biomedical technology industry in Hong. He has been consulting for several institutes and biomedical technology companies, holds Adjunct Professorship of Division of Life Science, Hong Kong University of Science and Technology, Honorary Professorships of Faculty of Medicine, University of Hong Kong, and School of Biomedical Sciences, Chinese University of Hong Kong. He is currently Associate Vice-President and Chief Innovation and Enterprise Officer, Office of Innovation and Enterprise of the Chinese University of Hong Kong.